BRPI0913643A2 - inibidores de ciclopropil polimerase - Google Patents

inibidores de ciclopropil polimerase

Info

Publication number
BRPI0913643A2
BRPI0913643A2 BRPI0913643A BRPI0913643A BRPI0913643A2 BR PI0913643 A2 BRPI0913643 A2 BR PI0913643A2 BR PI0913643 A BRPI0913643 A BR PI0913643A BR PI0913643 A BRPI0913643 A BR PI0913643A BR PI0913643 A2 BRPI0913643 A2 BR PI0913643A2
Authority
BR
Brazil
Prior art keywords
cyclopropyl
polymerase inhibitors
polymerase
inhibitors
cyclopropyl polymerase
Prior art date
Application number
BRPI0913643A
Other languages
English (en)
Inventor
Koen Vandyck
Pierre Jean-Marie Bernard Raboisson
Tim Hugo Maria Jonckers
Original Assignee
Centocor Ortho Biotech Products L P
Medivir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41095413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0913643(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centocor Ortho Biotech Products L P, Medivir Ab filed Critical Centocor Ortho Biotech Products L P
Publication of BRPI0913643A2 publication Critical patent/BRPI0913643A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0913643A 2008-07-01 2009-07-01 inibidores de ciclopropil polimerase BRPI0913643A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08159396 2008-07-01
EP08171005 2008-12-08
PCT/EP2009/004748 WO2010000459A1 (en) 2008-07-01 2009-07-01 Cyclopropyl polymerase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0913643A2 true BRPI0913643A2 (pt) 2015-11-24

Family

ID=41095413

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913643A BRPI0913643A2 (pt) 2008-07-01 2009-07-01 inibidores de ciclopropil polimerase

Country Status (29)

Country Link
US (1) US8431588B2 (pt)
EP (1) EP2141172B1 (pt)
JP (1) JP5624029B2 (pt)
KR (1) KR20110038683A (pt)
CN (2) CN105693794A (pt)
AP (1) AP2010005505A0 (pt)
AR (1) AR072428A1 (pt)
AU (1) AU2009266004B2 (pt)
BR (1) BRPI0913643A2 (pt)
CA (1) CA2729316A1 (pt)
CL (1) CL2010001634A1 (pt)
CO (1) CO6321255A2 (pt)
DK (1) DK2141172T3 (pt)
EA (1) EA022754B1 (pt)
EC (1) ECSP10010725A (pt)
ES (1) ES2396803T3 (pt)
HK (1) HK1226080A1 (pt)
HR (1) HRP20121068T1 (pt)
IL (1) IL209932A (pt)
MX (1) MX2010014493A (pt)
NI (1) NI201000231A (pt)
PL (1) PL2141172T3 (pt)
PT (1) PT2141172E (pt)
SI (1) SI2141172T1 (pt)
SV (1) SV2010003779A (pt)
TW (1) TW201012814A (pt)
UY (1) UY31950A (pt)
WO (1) WO2010000459A1 (pt)
ZA (1) ZA201009294B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3257887B1 (en) * 2008-09-08 2024-11-06 Saudi Aramco Technologies Company Polycarbonate polyol compositions and methods
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
TW201201815A (en) * 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
JP5845841B2 (ja) 2011-11-18 2016-01-20 東芝ライテック株式会社 照明制御装置
AU2013221571A1 (en) 2012-02-14 2014-08-28 University Of Georgia Research Foundation, Inc. Spiro [2.4] heptanes for treatment of Flaviviridae infections
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
GEAP202215528A (en) 2015-03-06 2022-11-10 Atea Pharmaceuticals Inc B-D-2'-DEOXY-2'a-FLUORO-2'-B-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
RU2590952C1 (ru) * 2015-05-26 2016-07-10 Вячеслав Энгельсович Семёнов Средство гепатопротекторного действия
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
BR112019004297A2 (pt) 2016-09-07 2019-05-28 Atea Pharmaceuticals Inc método, uso de uma quantidade eficaz de um composto, composto, e, composição farmacêutica.
SG11201906163TA (en) 2017-02-01 2019-08-27 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
JP2024525164A (ja) 2021-06-17 2024-07-10 アテア ファーマシューティカルズ， インコーポレイテッド 有利な抗ｈｃｖ併用療法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB0114286D0 (en) * 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
TW200500375A (en) * 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
CA2523083C (en) * 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
CN101044151B (zh) * 2004-08-23 2011-01-19 弗·哈夫曼-拉罗切有限公司 抗病毒的4＇-叠氮基-核苷
HRP20110193T1 (hr) * 2006-10-10 2011-05-31 Medivir Ab Inhibitor hcv nukleozida

Also Published As

Publication number Publication date
IL209932A0 (en) 2011-02-28
PT2141172E (pt) 2013-01-14
JP2011526270A (ja) 2011-10-06
EA022754B1 (ru) 2016-02-29
HRP20121068T1 (hr) 2013-01-31
ZA201009294B (en) 2012-06-27
KR20110038683A (ko) 2011-04-14
TW201012814A (en) 2010-04-01
AP2010005505A0 (en) 2010-12-31
AU2009266004B2 (en) 2014-01-30
ECSP10010725A (es) 2011-04-29
MX2010014493A (es) 2011-05-19
WO2010000459A1 (en) 2010-01-07
NI201000231A (es) 2011-09-03
CN102083845B (zh) 2016-09-14
EP2141172A1 (en) 2010-01-06
DK2141172T3 (da) 2013-01-21
EA201170118A1 (ru) 2011-06-30
UY31950A (es) 2010-01-29
CL2010001634A1 (es) 2011-08-05
SV2010003779A (es) 2011-02-08
CN105693794A (zh) 2016-06-22
CN102083845A (zh) 2011-06-01
EP2141172B1 (en) 2012-10-24
ES2396803T3 (es) 2013-02-27
CA2729316A1 (en) 2010-01-07
US8431588B2 (en) 2013-04-30
PL2141172T3 (pl) 2013-03-29
AU2009266004A1 (en) 2010-01-07
AR072428A1 (es) 2010-08-25
HK1226080A1 (zh) 2017-09-22
JP5624029B2 (ja) 2014-11-12
SI2141172T1 (sl) 2013-02-28
CO6321255A2 (es) 2011-09-20
IL209932A (en) 2013-12-31
US20110092460A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
FR20C1031I2 (fr) Inhibiteurs de beta-lactamase
BRPI0913643A2 (pt) inibidores de ciclopropil polimerase
BRPI0922681A2 (pt) nucleiotídeos de uracil ciclopropila
BRPI0916992A2 (pt) ferramenta de redução
EP2414109A4 (en) Metallic ink
EP2305306A4 (en) NEURO INVASION INHIBITOR
HUE040727T2 (hu) Hûtõberendezés
BRPI1016189A2 (pt) compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2
DK2511282T3 (da) Uracylspirooxetannukleosider
BR112012005382A2 (pt) inibidores de jak
IT1401535B1 (it) Portautensili
BRPI0906062A2 (pt) Inibidores de sinalização de brassinosteróides
BRPI0917673A2 (pt) Combinação de herbicida-protetor compreendendo difluorometanossulfonilanilidas substituidas por dimetoxitriazinila
EP2507208A4 (en) HARD OVERBASIC MAGNESIUM ALKYL TOLUOL SULPHONATE
BRPI0917563A2 (pt) porta-objeto
BR112013009461A2 (pt) inibidores de polimerase vitais
BR112012003059A2 (pt) inibidores de jnk
BRPI1011509A2 (pt) alargador
FI9115U1 (fi) Työväline
FI20095955L (fi) Käsityökalu
BRPI0921781A2 (pt) pipeta
DE102009026492A8 (de) Handwerkzeug
ES1068584Y (es) Torreta
TH0901005454A (th) สารประกอบไซโคลโพรพิล
GB0806913D0 (en) Polymerase inhibitors

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2598 DE 20-10-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.